|
Re: BET inhibition and epilepsy
|
6
|
Resverlogix Corp.
|
Jun 08, 2021 10:13AM
|
|
Re: Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
|
6
|
Resverlogix Corp.
|
Oct 22, 2018 10:28AM
|
|
REDUCE-IT CVOT Meets Primary Endpoint
|
6
|
Resverlogix Corp.
|
Sep 24, 2018 10:01AM
|
|
Re: Clarification on BETonMACE baseline data
|
6
|
Resverlogix Corp.
|
Sep 09, 2019 05:44PM
|
|
Re: Waiting for the shoe to drop....
|
6
|
Resverlogix Corp.
|
Apr 18, 2018 10:06PM
|
|
Re: ESPR results
|
6
|
Resverlogix Corp.
|
Aug 26, 2018 10:41AM
|
|
Re: Shrinking MACE event rate
|
6
|
Resverlogix Corp.
|
Jan 20, 2019 08:03AM
|
|
Re: An ESC video from youtube that mentions Apabetalone, posted July 10 2019
|
5
|
Resverlogix Corp.
|
Sep 09, 2019 05:54PM
|
|
Re: What if BETonMACE had more CKD patients?
|
5
|
Resverlogix Corp.
|
Dec 27, 2019 09:45AM
|
|
Re: Rough Transcript - Resverlogix Corporate Update and Conference Call - 06/10/2020
|
5
|
Resverlogix Corp.
|
Jun 11, 2020 02:44PM
|
|
Inflammation, hsCRP and apabetalone
|
5
|
Resverlogix Corp.
|
Jan 23, 2019 12:37PM
|
|
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
|
5
|
Resverlogix Corp.
|
Jul 25, 2017 10:42AM
|
|
Re: Blood test coming for Earlier Detection of Alzheimer's
|
5
|
Resverlogix Corp.
|
Mar 05, 2018 10:54PM
|
|
Re: A few comments
|
5
|
Resverlogix Corp.
|
Jan 12, 2017 11:21AM
|
|
Targeting Transcription Factors for Cancer Treatment
|
5
|
Zenith Epigenetics
|
Jun 22, 2018 10:59AM
|
|
Re: NLRP3 inhibitors and apabetalone
|
5
|
Resverlogix Corp.
|
Jul 26, 2019 02:28PM
|
|
Re: What if
|
5
|
Resverlogix Corp.
|
Mar 07, 2019 09:24AM
|
|
Re: If BP buys Apabetalone,...
|
5
|
Resverlogix Corp.
|
Nov 07, 2019 06:32AM
|
|
Re: Clarification received...
|
5
|
Resverlogix Corp.
|
Jun 10, 2018 08:23AM
|
|
Protein Biomarkers of Cardiovascular Disease and Mortality in the Community
|
5
|
Resverlogix Corp.
|
Jul 19, 2018 02:35PM
|
